



## **Emerald Health Pharmaceuticals to Present at the Rodman & Renshaw 20th Annual Global Investment Conference**

SAN DIEGO, CA, August 28, 2018 – Emerald Health Pharmaceuticals Inc. (EHP), a company developing medicines based on cannabinoid science, today announced that Jim DeMesa, MD Chief Executive Officer of EHP, will present a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference taking place at the St. Regis Hotel in New York, NY.

Presentation details are as follows:

Date: Thursday – September 6, 2018

Time: 3:00 PM Eastern Time

To view the live webcast, please access the following link at the time of the presentation: <http://www.wsw.com/webcast/rrshq28/ehpi>. An archived version of the webcast will be available for 90 days in the investor section of the Emerald Health Pharmaceuticals website.

### **About Emerald Health Pharmaceuticals Inc.**

Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of CNS, autoimmune, and other diseases. EHP has two families of new chemical entities, derivatives of synthetic cannabidiol (CBD), including EHP-101, and derivatives of cannabigerol (CBG), including EHP-102. These novel synthetic derivatives have been modified through rational drug design to affect validated receptors pertinent to targeted diseases. EHP-101 is focused on treating neurodegenerative and autoimmune diseases including multiple sclerosis and scleroderma. The company intends to launch a Phase I clinical study of EHP-101 in 2018. EHP-102 is in preclinical development and is currently focused on treating Huntington's disease and Parkinson's disease. Emerald Health Pharmaceuticals is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body's endocannabinoid system.

For more information, visit [www.emeraldpharma.life](http://www.emeraldpharma.life) or contact: [info@emeraldpharma.life](mailto:info@emeraldpharma.life).

*To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the Private Securities Litigation Reform Act of 1995, that reflect management's current beliefs and expectations. You can identify forward looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "hope," "hypothesis," "intend," "may," "plan," "potential," "predict," "project," "should," "strategy," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our*



*product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; and (v) our ability to meet our milestones. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.*